ArticleInnate immunity

Preclinical development of the TLR4 antagonist FP12 as a drug lead targeting the HMGB1/MD-2/TLR4 axis in lethal influenza infection.

Kari Ann Shirey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.